Metabolomic Clues to Multiple Sclerosis: Insights from a Mendelian Randomization Study
Multiple sclerosis is a chronic autoimmune disorder of the central nervous system characterized by demyelination, neuroinflammation, and progressive neurodegeneration. Although established risk factors such as Epstein–Barr virus infection, smoking, low vitamin D status, obesity, and sex-related susceptibility have been widely studied, the biochemical pathways that contribute causally to disease onset remain incompletely understood. The article “A metabolome-wide Mendelian randomization study prioritizes causal circulating metabolites for multiple sclerosis” addresses this gap by investigating whether circulating metabolites are merely associated with multiple sclerosis or may play causal roles in disease development.
Why Metabolomics Matters in Multiple Sclerosis
Metabolomics provides a high-resolution view of biochemical activity in the body and can reveal disease-related perturbations in amino acid metabolism, lipid metabolism, nucleotide turnover, and energy production. In multiple sclerosis, previous observational studies have reported altered concentrations of metabolites such as lysine, serine, uridine, acetone, acetoacetate, and several lipoprotein-associated lipids. However, observational metabolomics is vulnerable to confounding and reverse causation, particularly because metabolic changes may result from inflammation, disability, treatment, or disease progression rather than preceding disease onset. The study therefore uses Mendelian randomization to strengthen causal inference beyond conventional case-control comparisons.
Study Design and Analytical Framework
The authors performed a two-sample Mendelian randomization analysis using genetic variants as instrumental variables for circulating metabolites. Genetic associations with metabolites were obtained from three genome-wide association studies of the human blood metabolome, covering hundreds of metabolites, while genetic associations with multiple sclerosis were derived from a large International Multiple Sclerosis Genetics Consortium dataset including 14,802 cases and 26,703 controls. The primary statistical approach was the multiplicative random-effects inverse variance-weighted method, supplemented by sensitivity analyses including weighted median, weighted mode, MR-Egger, MR-PRESSO, and MR Steiger testing. This framework enabled the authors to evaluate both the magnitude and robustness of putative causal effects.
Principal Findings: Twenty-Nine Candidate Metabolites
The analysis identified 29 circulating metabolites with suggestive evidence of causal association with multiple sclerosis risk. Among the most prominent findings, genetically predicted higher levels of serine, lysine, acetone, and acetoacetate were associated with increased risk of multiple sclerosis. The reported odds ratios were particularly notable for acetone and acetoacetate, suggesting that ketone-body-related metabolism may be relevant to disease susceptibility. The study also highlighted uridine as a positively associated metabolite, supporting prior observations that nucleotide metabolism may be altered in multiple sclerosis.
Lipid Metabolism and Lipoprotein Subclasses
A major contribution of the article is its attention to lipid fractions within specific lipoprotein subclasses rather than broad lipid categories alone. The authors found that total cholesterol, phospholipids, and triglycerides in large very-low-density lipoprotein particles were associated with lower multiple sclerosis risk, whereas total cholesterol, phospholipids, and cholesterol esters in very large high-density lipoprotein particles were associated with higher risk. This distinction is biologically important because it suggests that lipid effects may depend on lipoprotein context, particle size, and transport dynamics. Such findings complicate simplistic interpretations of “good” or “bad” lipid classes and point toward more nuanced mechanisms linking lipid metabolism with neuroinflammation and myelin biology.
Amino Acids, Energy Metabolism, and Disease Mechanisms
The associations involving serine and lysine are especially intriguing because amino acid metabolism intersects with immune activation, cellular biosynthesis, and central nervous system repair. Serine is relevant to one-carbon metabolism and lipid synthesis, including pathways involved in phospholipids and sphingolipids that are essential for myelin structure. The findings for acetone and acetoacetate are also biologically provocative because ketone bodies may reflect altered energy metabolism. While ketogenic diets have been discussed as potentially beneficial in multiple sclerosis management, this study raises a separate question: whether genetically influenced ketone-body levels may also relate to disease risk before clinical onset.
Interpretation, Limitations, and Future Directions
This study provides a systematic prioritization of metabolites that may contribute causally to multiple sclerosis, but its conclusions should be interpreted with appropriate caution. The article is a medRxiv preprint and had not been certified by peer review at the time of posting. The analysis was restricted to individuals of European ancestry, some metabolites were excluded because they lacked sufficient genetic instruments, and Mendelian randomization cannot fully eliminate horizontal pleiotropy or define critical exposure windows. Nevertheless, the work offers a valuable hypothesis-generating framework for future mechanistic, clinical, and multi-ancestry studies. By prioritizing metabolites such as serine, lysine, acetone, acetoacetate, uridine, and lipoprotein-specific lipid fractions, the article advances a more causally informed view of metabolic pathways in multiple sclerosis pathogenesis.
Disclaimer: This blog post is based on the provided research article and is intended for informational purposes only. It is not intended to provide medical advice. Please consult with a healthcare professional for any health concerns.
References:
Ge, A., Sun, Y., Kiker, T., Zhou, Y., & Ye, K. (2022). A metabolome-wide Mendelian randomization study prioritizes causal circulating metabolites for multiple sclerosis. medRxiv, 2022-11.
